GSK and ChemoCentryx take novel Crohn's therapy into Phase III
This article was originally published in Scrip
GlaxoSmithKline and ChemoCentryx have begun full Phase III development for their potential oral anti-inflammatory treatment for Crohn's disease, GSK1605786 (formerly Traficet-EN).
You may also be interested in...
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.